DSM-Firmenich


Profitability disappoints in FY25

12/02/26 -"DSM’s full-year results aligned closely with expectations, achieving 3.0% organic revenue growth, just below the 3.1% consensus forecast (a 10bps shortfall). In Q4, organic growth slowed to ..."

Pages
61
Language
English
Published on
12/02/26
You may also be interested by these reports :
20/02/26
Umicore reported broadly flat YoY sales, in line with consensus. We expect a flattish sales growth into FY26 ex. metals exposure, as we anticipate ...

19/02/26
Of note: Cementir has been tracked by AlphaValue as part of a sponsored research contract since 2019. Cement is nobody’s instinctive climate ...

12/02/26
DSM’s full-year results aligned closely with expectations, achieving 3.0% organic revenue growth, just below the 3.1% consensus forecast (a 10bps ...

12/02/26
1H25/26 remained below expectations – Reduced FY25/26E sales guidance

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO